{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=17",
    "query": {
      "intervention": "Vehicle solution",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 454,
    "total_pages": 46,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+solution&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T16:37:31.593Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00245271",
      "title": "Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anterior Cruciate Ligament Reconstruction"
      ],
      "interventions": [
        {
          "name": "OMS103HP",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Omeros Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "17 Years to 65 Years"
      },
      "enrollment_count": 480,
      "start_date": "2004-10",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2011-06-27",
      "last_synced_at": "2026-10-20T16:37:31.593Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Redwood City, California • Denver, Colorado + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00245271"
    },
    {
      "nct_id": "NCT03464292",
      "title": "Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fibromyalgia",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Capsaicin Patch 8% or 0.1% Capsaicin Cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Patch",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 55,
      "start_date": "2018-07-05",
      "completion_date": "2023-12-08",
      "has_results": false,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-10-20T16:37:31.593Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03464292"
    },
    {
      "nct_id": "NCT01681290",
      "title": "Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "CBX129801",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cebix Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 250,
      "start_date": "2012-10",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2015-01-30",
      "last_synced_at": "2026-10-20T16:37:31.593Z",
      "location_count": 22,
      "location_summary": "Escondido, California • Fresno, California • Irvine, California + 18 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01681290"
    },
    {
      "nct_id": "NCT02329743",
      "title": "Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Inflammation",
        "Pain",
        "Cataract"
      ],
      "interventions": [
        {
          "name": "RX-10045",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "A.T. Resolve SARL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 256,
      "start_date": "2014-12",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2019-02-20",
      "last_synced_at": "2026-10-20T16:37:31.593Z",
      "location_count": 1,
      "location_summary": "Murray Hill, New Jersey",
      "locations": [
        {
          "city": "Murray Hill",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02329743"
    },
    {
      "nct_id": "NCT06441643",
      "title": "Next Generation Rocklatan",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "AR-17043 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "PG043 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil 0.02% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "AR-17043 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 426,
      "start_date": "2024-09-04",
      "completion_date": "2025-11-14",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-10-20T16:37:31.593Z",
      "location_count": 12,
      "location_summary": "Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06441643"
    },
    {
      "nct_id": "NCT01771822",
      "title": "Ibuprofen 5% Topical Gel CIPT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Ibuprofen 5% topical gel",
          "type": "DRUG"
        },
        {
          "name": "Topical gel vehicle",
          "type": "DRUG"
        },
        {
          "name": "Sodium lauryl sulfate 0.2%",
          "type": "DRUG"
        },
        {
          "name": "Sodium chloride solution 0.9% (saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2013-01",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-10-20T16:37:31.593Z",
      "location_count": 1,
      "location_summary": "Carlstadt, New Jersey",
      "locations": [
        {
          "city": "Carlstadt",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01771822"
    },
    {
      "nct_id": "NCT02669862",
      "title": "A Study of A-101 Solution in Subjects With Common Warts.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Common Warts"
      ],
      "interventions": [
        {
          "name": "A-101 Solution 40",
          "type": "DRUG"
        },
        {
          "name": "A-101 Solution 45",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2015-12-21",
      "completion_date": "2016-09-16",
      "has_results": true,
      "last_update_posted_date": "2018-12-07",
      "last_synced_at": "2026-10-20T16:37:31.593Z",
      "location_count": 1,
      "location_summary": "Wayne, Pennsylvania",
      "locations": [
        {
          "city": "Wayne",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02669862"
    },
    {
      "nct_id": "NCT01848041",
      "title": "Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Blepharoptosis"
      ],
      "interventions": [
        {
          "name": "RVL-1201",
          "type": "DRUG"
        },
        {
          "name": "RVL-1201 Vehicle Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RVL Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2013-05",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2021-11-26",
      "last_synced_at": "2026-10-20T16:37:31.593Z",
      "location_count": 1,
      "location_summary": "Morrow, Georgia",
      "locations": [
        {
          "city": "Morrow",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848041"
    },
    {
      "nct_id": "NCT01134328",
      "title": "Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "AC-150 Combo",
          "type": "DRUG"
        },
        {
          "name": "AC-150A 0.1%",
          "type": "DRUG"
        },
        {
          "name": "AC-150B 0.005%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aciex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2010-05",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2017-09-14",
      "last_synced_at": "2026-10-20T16:37:31.593Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01134328"
    },
    {
      "nct_id": "NCT02493257",
      "title": "Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonallergic Irritant Rhinitis"
      ],
      "interventions": [
        {
          "name": "Capsaicin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 22,
      "start_date": "2014-10",
      "completion_date": "2019-08-02",
      "has_results": true,
      "last_update_posted_date": "2020-08-17",
      "last_synced_at": "2026-10-20T16:37:31.593Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02493257"
    }
  ]
}